News

Press Releases

April 26, 2022
Oncoc4 Announces Fast Track Designation Granted By The U.S. FDA For ONC-392 Monotherapy In PD(L)1-Resistant NSCLC

A Phase 1b clinical trial of ONC-392 in PD(L)1-resistant NSCLC is currently underway April 25, 2022, Rockville, Maryland — OncoC4, Inc., […]

Read more
April 1, 2022
Dr. Yang Liu Acknowledged as Top 20 Dynamic CEOs of 2022

ROCKVILLE, Md., Mar. 31, 2022 – The CEO Publication, a unique digital platform featuring the industry experts who have created […]

Read more
March 15, 2022
OncoC4 Recognized as a Top 10 Immunotherapy Solutions Providers

ROCKVILLE, Md., Mar. 15, 2022 – OncoC4, Inc. is recognized by Pharma Tech Outlook as one of the “Top 10 Immunotherapy […]

Read more
February 18, 2022
Dr. Pan Zheng of OncoC4 is Inducted into the 2022 College of Fellow of AIMBE

ROCKVILLE, Md., Feb. 18, 2022 – OncoC4, Inc. is elated to announce that its co-founder and Chief Medical Officer, Dr. Pan […]

Read more
November 9, 2021
OncoC4, Inc. Reports Phase Ia Data on Safety and Clinical Activities of ONC-392 (Nextgen Anti-CTLA-4) Monotherapy for Stage IV Solid Tumors

ROCKVILLE, Md., Nov. 09, 2021 — OncoC4, Inc., a clinical stage biopharma company focusing on immuno-oncology of cancer, reports a […]

Read more
Scroll to Top